Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature

Regarding the prognosis of cases with advanced-stage hepatocellular carcinoma (HCC), a recent clinical study showed that the immune checkpoint inhibitors atezolizumab plus bevacizumab have superior efficacy to sorafenib. However, only a few reports have focused on their effects on extrahepatic metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Natsuki, Kamimura, Kenya, Endo, Saori, Ishii, Soichi, Ogawa, Kazuya, Sakai, Norihiro, Abe, Hiroyuki, Ko, Masayoshi, Shibata, Osamu, Koseki, Youhei, Yokoyama, Junji, Sakamaki, Akira, Terai, Shuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683801/
https://www.ncbi.nlm.nih.gov/pubmed/35431306
http://dx.doi.org/10.2169/internalmedicine.9341-22
Descripción
Sumario:Regarding the prognosis of cases with advanced-stage hepatocellular carcinoma (HCC), a recent clinical study showed that the immune checkpoint inhibitors atezolizumab plus bevacizumab have superior efficacy to sorafenib. However, only a few reports have focused on their effects on extrahepatic metastases. We herein report a case of HCC in a 59-year-old man with intrahepatic lesions treated successfully by hepatic arterial chemoembolization, radiotherapy, and sorafenib; the extrahepatic lesion in the adrenal gland was treated by atezolizumab plus bevacizumab. The patient showed a tumor-free condition for one year. We have summarized the clinical course and reviewed the literature to underscore the efficacy of atezolizumab plus bevacizumab for treating extrahepatic lesions of HCC.

Ejemplares similares